DENNIS MOORE, MD
Hematology & Oncology Physician · WICHITA, KS
Individual Active NPI 1043272305
Medicare payment data Part B · 2024
| Year | Beneficiaries | Services | Submitted | Allowed | Paid |
|---|---|---|---|---|---|
| 2024 | 1,713 | 533,866 | $42,696,407 | $12,157,304 | $9,673,691 |
| 2023 | 1,534 | 465,810 | $31,256,973 | $11,150,586 | $8,881,208 |
| 2022 | 1,117 | 349,135 | $14,178,777 | $7,132,142 | $5,673,104 |
Top procedures (2024)
| HCPCS | Description | Services | Avg allowed | Avg paid |
|---|---|---|---|---|
| Q5110 | Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | 50,940 | $0 | $0 |
| J9271 | Injection, pembrolizumab, 1 mg | 50,800 | $56 | $45 |
| J0185 | Injection, aprepitant, 1 mg | 41,990 | $2 | $1 |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | 29,520 | $49 | $39 |
| J9263 | Injection, oxaliplatin, 0.5 mg | 29,132 | $0 | $0 |
| J1627 | Injection, granisetron, extended-release, 0.1 mg | 26,500 | $6 | $4 |
| J1439 | Injection, ferric carboxymaltose, 1 mg | 25,500 | $1 | $1 |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 23,655 | $3 | $2 |
| J9299 | Injection, nivolumab, 1 mg | 19,740 | $31 | $25 |
| J0897 | Injection, denosumab, 1 mg | 17,340 | $26 | $21 |
| J9267 | Injection, paclitaxel, 1 mg | 14,445 | $0 | $0 |
| J1449 | Injection, eflapegrastim-xnst, 0.1 mg | 14,124 | $27 | $21 |
Taxonomy & licensure
| Specialty | Code | Primary | License | State |
|---|---|---|---|---|
| Hematology & Oncology Physician | 207RH0003X | ✓ | 0423400 | KS |
Medicare eligibility
- Part B
- Yes
- DME
- Yes
- Home health
- Yes
- Power mobility
- Yes
- Hospice
- Yes
Other Hematology & Oncology Physician providers in Kansas
- NPI 1053372649
- NPI 1841251394
- NPI 1821249137
- NPI 1972721348
- NPI 1336451665
- NPI 1528263043
- NPI 1750777959
- NPI 1528029147
See all Hematology & Oncology Physician providers in Kansas →
Source: NPPES (public domain) and CMS Medicare Physician & Other Practitioners data. Not affiliated with CMS, NPPES, or any government agency.